Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.
Jayavelu ND, Qi J, Milliren CE, Ozonoff A, Liu S, Levy O, Baden LR, Melamed E, McComsey GA, Cairns CB, Schaenman J, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Geng LN, Sesma AF, Simon V, Krammer F, Bime C, Calfee CS, Bosinger SE, Eckalbar W, Steen H, Maecker HT; IMPACC Network; Augustine AD, Diray-Arce J, Haddad EK, Sekaly RP, Kraft M, Woodruff PG, Erle DJ, Ehrlich LIR, Montgomery RR, Becker PM, Altman MC, Fourati S.
Jayavelu ND, et al.
J Allergy Clin Immunol Glob. 2025 Jun 12;4(4):100515. doi: 10.1016/j.jacig.2025.100515. eCollection 2025 Nov.
J Allergy Clin Immunol Glob. 2025.
PMID: 40709330
Free PMC article.